Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Express Scripts
QuintilesIMS
Boehringer Ingelheim
Harvard Business School
Fish and Richardson

Generated: September 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INGENOL MEBUTATE

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Clinical Trials for Ingenol Mebutate

Trial ID Title Status Sponsor Phase Summary
NCT00742391 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations Completed Peplin Phase 3 The purpose of this study is to determine whether topical application of PEP005 is effective for the treatment of actinic keratoses.
NCT00850681 A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers Completed Peplin Phase 1 This Phase 1 study is designed to determine the photoallergic potential of PEP005 Gel, 0.01% and it's vehicle on normal skin.
NCT00850811 A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers Completed Peplin Phase 1 This Phase 1 study is designed to determine the photoirritation potential of PEP005 Gel, 0.01% when application is followed by light exposure.
NCT00852137 A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis Completed Peplin Phase 2 This Phase II study is designed to evaluate the pharmacokinetics of PEP005 (ingenol mebutate) Gel, 0.05% when applied in a maximal use setting to the dorsal aspect of the forearm in patients with actinic keratoses
NCT00915551 A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp) Completed Peplin Phase 3 This Phase III study is designed to assess the efficacy and safety of PEP005 Gel, 0.015% when applied to an area of skin containing 4-8 AK lesions on the face or scalp.
NCT00916006 A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp) Completed Peplin Phase 3 This Phase III study is designed to assess the efficacy and safety of PEP005 Gel, 0.015% when applied to an area of skin containing 4-8 AK lesions on the face or scalp.
NCT00917306 A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities) Completed TKL Research, Inc. Phase 3 The open label study is designed to assess the safety and efficacy of 0.05% PEP005 Gel when applied to an area of skin containing 4-8 AK lesions on non-head locations.
>Trial ID >Title >Status >Phase >Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Ingenol Mebutate

Condition Name

Condition Name for Ingenol Mebutate
Intervention Trials
Actinic Keratosis 33
Actinic Keratoses 5
Actinic Keratosis (AK) 2
Seborrheic Keratosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ingenol Mebutate
Intervention Trials
Keratosis, Actinic 42
Keratosis 42
Carcinoma 3
Carcinoma, Basal Cell 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ingenol Mebutate

Trials by Country

Trials by Country for Ingenol Mebutate
Location Trials
United States 100
Australia 20
United Kingdom 15
Canada 7
Germany 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ingenol Mebutate
Location Trials
California 9
New York 8
Indiana 8
Texas 7
Florida 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ingenol Mebutate

Clinical Trial Phase

Clinical Trial Phase for Ingenol Mebutate
Clinical Trial Phase Trials
Phase 4 8
Phase 3 11
Phase 2 8
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ingenol Mebutate
Clinical Trial Phase Trials
Completed 30
Recruiting 8
Active, not recruiting 5
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ingenol Mebutate

Sponsor Name

Sponsor Name for Ingenol Mebutate
Sponsor Trials
LEO Pharma 27
Peplin 12
Icahn School of Medicine at Mount Sinai 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ingenol Mebutate
Sponsor Trials
Industry 42
Other 27
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Johnson and Johnson
QuintilesIMS
Cantor Fitzgerald
Julphar
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.